Patient Segmentation in ALS Studies

Does genotypic vs. phenotypic segmentation make sense in the context of an amyotrophic lateral sclerosis (ALS) study?

May 14, 2021
Michael Murphy, MD, PhD | Tom Babic, MD, PhD | Andrew Kuhlman | Erin Griner | William Slone

In a new article, a group of CNS experts at Worldwide Clinical Trials explore the relationship between genetic mutations and phenotypic characteristics of amyotrophic lateral sclerosis (ALS). This article, entitled “Patient Segmentation in ALS Studies,” appears in the Journal of Clinical Research and poses the question: Does genotypic vs. phenotypic segmentation make sense in the context of an ALS study?

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE
Tom Babic, MD, PhD
MEET THE AUTHOR

Tom Babic, MD, PhD

Vice President, Scientific Solutions, Neuroscience
LEARN MORE